Cynfonera 10Mg & 20Mg 10 mg, 20 mg FC TABLETS
PDF Leaflet Revision Date: 18 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of chronic kidney disease stage 3 and 4 with albuminuria associated with type 2 diabetes in adults.
Dosage (summary)
Target dose: 20 mg once daily; max dose: 20 mg once daily; starting dose based on eGFR.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Potassium-sparing diuretics
- Trimethoprim
Contraindications
- Hypersensitivity to finerenone
- Severe hepatic impairment
- Concomitant use with strong CYP3A4 inhibitors
Common side effects
- Hyperkalaemia
- Hypotension
- Hyponatraemia
Counselling Points
- Take with or without food; avoid grapefruit.
- Monitor potassium levels regularly.
- Use effective contraception during treatment.
Serious warnings
- Risk of hyperkalaemia
- Monitoring of serum potassium required
Important Disclaimer
The Cynfonera 10Mg & 20Mg 10 mg, 20 mg FC TABLETS professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
